Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

Core Insights - Precipio, Inc. has reported strong preliminary financial results for Q4-2025 and fiscal year 2025, highlighting significant growth in revenue and positive cash flow metrics [1][5]. Financial Performance - Revenue Growth: Precipio's revenues increased from $18.5 million in 2024 to $24.0 million in 2025, representing a 30% year-over-year increase. Q4-2025 revenues were $6.7 million, up 23% from $5.4 million in Q4-2024 [5]. - Positive Adjusted EBITDA: The company will report Adjusted EBITDA of $0.95 million for Q4-2025 and $1.23 million for the full year 2025, compared to $0.40 million in Q4-2024 and a loss of $1.5 million for the full year 2024 [5]. - Positive Operating Cash Flow: Precipio will report $368,000 of positive operating cash flow during Q4-2025 and a total of $688,000 for 2025, compared to $439,000 generated from operations in 2024 [5]. Management Commentary - The CEO, Ilan Danieli, emphasized the importance of becoming an EBITDA and cash-flow positive business, allowing for investments in long-term growth projects rather than focusing solely on short-term cash burn [2]. The company experienced a strong performance in 2025, with shareholders seeing their value triple [2]. Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [6].